News Article | November 7, 2016
This report studies sales (consumption) of Global Immunoassay Analyzer Market 2016, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Abbott Diagnostics Euroimmun Beckman Coulter BioMerieux Roche Diagnostics Randox Laboratories Adaltis DiaSorin Tosoh Dynex Technologies DRG International, Inc. BD Diagnostics Boditech Med Meril Life Sciences Ortho Clinical Diagnostics STRATEC Biomedical AG Aesku.Diagnostics Biokit Shenzhen New Industries Biomedical Engineering Trinity Biotech plc. Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Immunoassay Analyzer in these regions, from 2011 to 2021 (forecast), like United States China Europe Japan Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into Type I Type II Type III Split by applications, this report focuses on sales, market share and growth rate of Immunoassay Analyzer in each application, can be divided into Oncology and endocrinology Hepatitis and Retrovirus testing Infectious disease testing GI stool testing Others Global Immunoassay Analyzer Sales Market Report 2016 1 Immunoassay Analyzer Overview 1.1 Product Overview and Scope of Immunoassay Analyzer 1.2 Classification of Immunoassay Analyzer 1.2.1 Type I 1.2.2 Type II 1.2.3 Type III 1.3 Application of Immunoassay Analyzer 1.3.1 Oncology and endocrinology 1.3.2 Hepatitis and Retrovirus testing 1.3.3 Infectious disease testing 1.3.4 GI stool testing 1.3.5 Others 1.4 Immunoassay Analyzer Market by Regions 1.4.1 United States Status and Prospect (2011-2021) 1.4.2 China Status and Prospect (2011-2021) 1.4.3 Europe Status and Prospect (2011-2021) 1.4.4 Japan Status and Prospect (2011-2021) 1.5 Global Market Size (Value and Volume) of Immunoassay Analyzer (2011-2021) 1.5.1 Global Immunoassay Analyzer Sales and Growth Rate (2011-2021) 1.5.2 Global Immunoassay Analyzer Revenue and Growth Rate (2011-2021) 7 Global Immunoassay Analyzer Manufacturers Analysis 7.1 Abbott Diagnostics 7.1.1 Company Basic Information, Manufacturing Base and Competitors 7.1.2 Immunoassay Analyzer Product Type, Application and Specification 184.108.40.206 Type I 220.127.116.11 Type II 7.1.3 Abbott Diagnostics Immunoassay Analyzer Sales, Revenue, Price and Gross Margin (2011-2016) 7.1.4 Main Business/Business Overview 7.2 Euroimmun 7.2.1 Company Basic Information, Manufacturing Base and Competitors 7.2.2 110 Product Type, Application and Specification 18.104.22.168 Type I 22.214.171.124 Type II 7.2.3 Euroimmun Immunoassay Analyzer Sales, Revenue, Price and Gross Margin (2011-2016) 7.2.4 Main Business/Business Overview 7.3 Beckman Coulter 7.3.1 Company Basic Information, Manufacturing Base and Competitors 7.3.2 136 Product Type, Application and Specification 126.96.36.199 Type I 188.8.131.52 Type II 7.3.3 Beckman Coulter Immunoassay Analyzer Sales, Revenue, Price and Gross Margin (2011-2016) 7.3.4 Main Business/Business Overview 7.4 BioMerieux 7.4.1 Company Basic Information, Manufacturing Base and Competitors 7.4.2 Nov Product Type, Application and Specification 184.108.40.206 Type I 220.127.116.11 Type II 7.4.3 BioMerieux Immunoassay Analyzer Sales, Revenue, Price and Gross Margin (2011-2016) 7.4.4 Main Business/Business Overview 7.5 Roche Diagnostics 7.5.1 Company Basic Information, Manufacturing Base and Competitors 7.5.2 Product Type, Application and Specification 18.104.22.168 Type I 22.214.171.124 Type II 7.5.3 Roche Diagnostics Immunoassay Analyzer Sales, Revenue, Price and Gross Margin (2011-2016) 7.5.4 Main Business/Business Overview 7.6 Randox Laboratories 7.6.1 Company Basic Information, Manufacturing Base and Competitors 7.6.2 Million USD Product Type, Application and Specification 126.96.36.199 Type I 188.8.131.52 Type II 7.6.3 Randox Laboratories Immunoassay Analyzer Sales, Revenue, Price and Gross Margin (2011-2016) 7.6.4 Main Business/Business Overview 7.7 Adaltis 7.7.1 Company Basic Information, Manufacturing Base and Competitors 7.7.2 Medical Devices Product Type, Application and Specification 184.108.40.206 Type I 220.127.116.11 Type II 7.7.3 Adaltis Immunoassay Analyzer Sales, Revenue, Price and Gross Margin (2011-2016) 7.7.4 Main Business/Business Overview 7.8 DiaSorin 7.8.1 Company Basic Information, Manufacturing Base and Competitors 7.8.2 Product Type, Application and Specification 18.104.22.168 Type I 22.214.171.124 Type II 7.8.3 DiaSorin Immunoassay Analyzer Sales, Revenue, Price and Gross Margin (2011-2016) 7.8.4 Main Business/Business Overview 7.9 Tosoh 7.9.1 Company Basic Information, Manufacturing Base and Competitors 7.9.2 Product Type, Application and Specification 126.96.36.199 Type I 188.8.131.52 Type II 7.9.3 Tosoh Immunoassay Analyzer Sales, Revenue, Price and Gross Margin (2011-2016) 7.9.4 Main Business/Business Overview 7.10 Dynex Technologies 7.10.1 Company Basic Information, Manufacturing Base and Competitors 7.10.2 Product Type, Application and Specification 184.108.40.206 Type I 220.127.116.11 Type II 7.10.3 Dynex Technologies Immunoassay Analyzer Sales, Revenue, Price and Gross Margin (2011-2016) 7.10.4 Main Business/Business Overview 7.11 DRG International, Inc. 7.12 BD Diagnostics 7.13 Boditech Med 7.14 Meril Life Sciences 7.15 Ortho Clinical Diagnostics 7.16 STRATEC Biomedical AG 7.17 Aesku.Diagnostics 7.18 Biokit 7.19 Shenzhen New Industries Biomedical Engineering 7.20 Trinity Biotech plc. Global QYResearch (http://globalqyresearch.com/ ) is the one spot destination for all your research needs. Global QYResearch holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports caters to various industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making purchase decision by understanding their requirements and suggesting best possible collection matching their needs.
Mortensen J.E.,Cincinnati Childrens Hospital |
Ventrola C.,Cincinnati Childrens Hospital |
Hanna S.,Cincinnati Childrens Hospital |
Walter A.,BD Diagnostics
BMC Clinical Pathology | Year: 2015
Background: Conventional bacterial stool culture is one of the more time-consuming tests in a routine clinical microbiology laboratory. In addition, less than 5 % of stool cultures yield positive results. A molecular platform, the BD MAX™ System (BD Diagnostics, Sparks, MD) offers the potential for significantly more rapid results and less hands-on time. Time-motion analysis of the BD MAX Enteric Bacterial Panel (EBP) (BD Diagnostics, Quebec, Canada) on the BD MAX System was compared to conventional stool culture in the microbiology laboratory of a tertiary care pediatric hospital. Methods: The process impact analysis of time-motion studies of conventional cultures were compared to those of EBP with 86 stool specimens. Sample flow, hands-on time, processing steps, and overall turnaround time were determined and analyzed. Data were obtained and analyzed from both standard operating procedures and direct observation. A regression analysis was performed to ensure consistency of measurements. Time and process measurements started when the specimens were logged into the accessioning area of the microbiology laboratory and were completed when actionable results were generated. Results: With conventional culture, negative culture results were available from 41:14:27 (hours:minutes:seconds) to 54:17:19; with EBP, positive and negative results were available from 2:28:40 to 3:33:39. Conclusions: This study supports the suggestion that use of the EBP to detect commonly encountered stool pathogens can result in significant time savings and a shorter time-to-result for patients with acute bacterial diarrhea. © 2015 Mortensen et al.; licensee BioMed Central.
Yi J.,BD Diagnostics |
Warunek D.,BD Diagnostics |
Craft D.,BD Diagnostics
PLoS ONE | Year: 2015
Plasma hormone peptides, including GLP-1, GIP, Glucagon, and OXM, possess multiple physiological roles and potential therapeutic and diagnostic utility as biomarkers in the research of metabolic disorders. These peptides are subject to proteolytic degradation causing preanalytical variations. Stabilization for accurate quantitation of these active peptides in ex vivo blood specimens is essential for drug and biomarker development. We investigated the protease-driven instability of these peptides in conventional serum, plasma, anticoagulated whole blood, as well as whole blood and plasma stabilized with protease inhibitors. The peptide was monitored by both time-course Matrix-Assisted Laser Desorption Ionization Time-to-Flight Mass Spectrometry (MALDI -TOF MS) and Ab-based assay (ELISA or RIA). MS enabled the identification of proteolytic fragments. In non-stabilized blood samples, the results clearly indicated that dipeptidyl peptidase-IV (DPP-IV) removed the N-terminal two amino acid residues from GLP-1, GIP and OXM(1-37) and notyet identified peptidase(s) cleave(s) the full-length OXM(1-37) and its fragments. DPP-IV also continued to remove two additional N-terminal residues of processed OXM(3-37) to yield OXM(5-37). Importantly, both DPP-IV and other peptidase(s) activities were inhibited efficiently by the protease inhibitors included in the BD P800∗ tube. There was preservation of GLP-1, GIP, OXM and glucagon in the P800 plasma samples with half-lives > 96, 96, 72, and 45 hours at room temperature (RT), respectively. In the BD P700∗ plasma samples, the stabilization of GLP-1 was also achieved with half-life > 96 hours at RT. The stabilization of these variable peptides increased their utility in drug and/or biomarker development. While stability results of GLP-1 obtained with Ab-based assay were consistent with those obtained by MS analysis, the Ab-based results of GIP, Glucagon, and OXM did not reflect the timedependent degradations revealed by MS analysis. Therefore, we recommended characterizing the degradation of the peptide using the MS-based method when investigating the stability of a specific peptide. Copyright © 2015 Yi et al.
Strauss S.,Reading Hospital |
Bourbeau P.P.,BD Diagnostics
Journal of Clinical Microbiology | Year: 2015
This study compared results from plating urine specimens with the BD InoqulA instrument using a 10-μl inoculum with results from cultures plated manually with a 1-μl loop for comparable 2-month periods. The positivity rates, turnaround times for positive cultures, and BD Phoenix identification and antimicrobial susceptibility test results were comparable for both time periods. We experienced no problems with culture interpretation as the result of moving to the 10-μl inoculum. Copyright © 2015, American Society for Microbiology. All Rights Reserved.
Fernandes H.,MSB C578 |
Morosyuk S.,BD Diagnostics |
Abravaya K.,Abbott Laboratories |
Ramanathan M.,MSB C578 |
Rainen L.,BD Diagnostics
Journal of Clinical Microbiology | Year: 2010
HIV-1 viral load testing is essential to the management of HIV-1-infected patients, and proper specimen handling ensures accurate viral load (VL) results. This study was performed to (i) evaluate the effect of freezing plasma in situ in BD Vacutainer plasma preparation tubes (PPT) on the accuracy of HIV-1 viral load results using the Abbott RealTime HIV-1 assay and (ii) evaluate the effect of whole-blood storage in the PPT for 6 h at room temperature prior to centrifugation (PPT6H) rather than 2 h as specified in the PPT product insert. Of the 64 HIV-positive subjects evaluated, 29 had average viral load counts of >40 copies/ml in at least one of the tubes tested and 35 subjects had a result of either "undetected target" or "below the limit of quantification" (LOQ) for all or some of the tubes regardless of handling condition. For the 29 subjects with VLs that were >LOQ, the mean biases between plasma from Vacutainer K2EDTA tubes and plasma frozen in situ in PPT and between K2EDTA tube plasma and plasma from PPT6H (log10 copies/ml) were 0.005 and -0.001, respectively, and r 2 was >0.92 for all correlations. We conclude that VLs determined from plasma frozen in situ in PPT are equivalent to VLs in K2EDTA tube plasma and can be used for accurate quantification of HIV-1 RNA in the Abbott RealTime HIV-1 assay. Furthermore specimens collected in PPT can be stored for 6 h at room temperature with no effect on viral load results as measured by the Abbott RealTime HIV-1 assay. Copyright © 2010, American Society for Microbiology. All Rights Reserved.
Cuellar-Rodriguez J.,National Institute of Allergy and Infectious Diseases |
Connor D.,University of Pittsburgh |
Murray P.,BD Diagnostics |
Gea-Banacloche J.,U.S. National Cancer Institute
European Journal of Clinical Microbiology and Infectious Diseases | Year: 2014
It is unclear whether blood culture samples should be obtained through one or multiple catheter lumens. We measured how frequently drawing blood cultures from all the lumens from a multilumen catheter resulted in discordant results and how often these caused medical interventions. We performed a retrospective review of the microbiology database of the National Institutes of Health (NIH) Clinical Center. Most patients were immunocompromised. All blood cultures obtained from May 1, 2007 to April 30, 2009 were reviewed. We analyzed all positive blood cultures (i.e., positivity of any of the blood cultures drawn through the catheter lumens) when simultaneous samples from different lumens were obtained, and reviewed the medical charts of those in which blood cultures from different lumens had discordant results (i.e., not all lumens revealed the same organism). We also analyzed how often the discordant results lead to a medical intervention, defined as a change of antimicrobials and/or removal of the catheter. There were 405 episodes of positive blood cultures, in which simultaneous samples of different lumens of a multilumen catheter were obtained. Eighty-five episodes (21 %) were considered to be contaminants and excluded. We analyzed 320 episodes of positive blood cultures in 153 patients; 173 episodes (54.1 %) had discordant results. In 77 % of the 173 episodes, the discordant isolate led to a medical intervention. In immunocompromised patients, sampling all the lumens of a multilumen catheter results in more positive blood cultures, and many of these result in medical interventions. When evaluating bloodstream infection in patients with multilumen catheters, sampling all lumens should be strongly considered. © 2013 Springer-Verlag.
Islinger M.,University of Heidelberg |
Eckerskorn C.,BD Diagnostics |
Volkl A.,University of Heidelberg
Electrophoresis | Year: 2010
Since its introduction five decades ago, free-flow electrophoresis (FFE) has been mainly employed for the isolation and fractionation of cells, cell organelles and protein mixtures. In the meantime, the growing interest in the proteome of these bio-particles and biopolymers has shed light on two further facets in the potential of FFE, namely its applicability as an analytical tool and sensor. This review is intended to outline recent innovations, FFE has gained in the proteomic era, and to point out the valuable contributions it has made to the analysis of the proteome of cells, sub-cellular organelles and functional protein networks. © 2010 Wiley-VCH Verlag GmbH & Co. KGaA.
Patel P.A.,NorthShore University HealthSystem |
Ledeboer N.A.,Medical College of Wisconsin |
Ginocchio C.C.,NorthShore Long Island J Health System Laboratories |
Condon S.,NorthShore Long Island J Health System Laboratories |
And 4 more authors.
Journal of Clinical Microbiology | Year: 2011
We evaluated the BD GeneOhm MRSA achromopeptidase (ACP) assay, which incorporates a new specimen preparation approach. A total of 1,216 leftover nasal samples were tested; using culture as the gold standard, the sensitivity and specificity were 92% and 94.6%, respectively. The new lysis method provides good sensitivity and simplifies specimen preparation. Copyright © 2011, American Society for Microbiology. All Rights Reserved.
Simundic A.-M.,University of Zagreb |
Cornes M.,Hospitals NHS Trust |
Grankvist K.,Umeå University |
Lippi G.,Academic Hospital of Parma |
And 5 more authors.
Clinical Chemistry and Laboratory Medicine | Year: 2013
Background: European questionnaire survey was conducted by the European Federation of Clinical Chemistry and Laboratory Medicine Working Group for the Preanalytical Phase (EFLM WG-PA) to assess how phlebotomy is performed in EFLM countries, including differences in personnel, level of education and skills, and to investigate the presence and compliance of national phlebotomy guidelines on this matter. Methods: A questionnaire was constructed containing questions elucidating different aspects of the organization behind the phlebotomy praxis on a national basis, including questions on the staff performing phlebotomy, the education of these staff members, and the existence of and adherence to national guidelines. All 39 EFLM member countries were invited to participate. Results: In total 28/39 (72%) EFLM member countries responded. Seven out of the 28 (25%) have national phlebotomy guidelines and five have implemented other guidelines. The estimated compliance with phlebotomy guidance for the laboratories in the countries that have national guidelines available is poor, regardless to whether the phlebotomy was under the laboratory control or not. Most countries were interested in EFLM guidelines and to participate in a pilot EFLM preanalytical phase external quality assessment (EQA) scheme. In the responding EFLM member countries, the majority of phlebotomy is performed by nurses and laboratory technicians. Their basic education is generally 4-5 years of high school, followed by 2-5 years of colleague or university studies. Only a third (10/28; 36%) of the participating member countries has any specific training available as a continuous educational resource. A specific training for phlebotomy is not part of the education required to become qualified in 6/28 (21%) and 9/28 (32%) of countries for nurses and laboratory technicians, respectively. In countries and professions where training is required, most require more than 5 h of training. Conclusions: Based on the results of this survey we conclude the following: 1) There is a need to assess the quality of current practices, compliance to the CLSI H3-A6 guidelines and to identify some most critical steps which occur during phlebotomy, in different healthcare settings, across Europe; 2) Existing CLSI H3-A6 phlebotomy guidelines should be adapted and used locally in all European countries which do not have their own guidelines; 3) National EFLM societies need to be engaged in basic training program development and continuous education of healthcare phlebotomy staff (implementing the certification of competence). © 2013 by Walter de Gruyter Berlin Boston 2013.
Yi J.,BD Diagnostics |
Craft D.,BD Diagnostics |
Gelfand C.A.,BD Diagnostics
Methods in Molecular Biology | Year: 2011
Blood samples collected for proteome studies are subject to a variety of preanalytical instability, among which intrinsic proteolysis activities cause a broad spectrum of protein and peptide degradation. This chapter describes two MALDI MS-based methods for plasma peptidomic analyses; a direct MALDI-TOF MS and an LC MALDI-TOF MS. Using these methods, we compared peptides and their time-dependent changes in traditional serum, four plasma samples with different anticoagulants and additives: EDTA-based, citrate-based, or heparin-based, and EDTA-based with protease inhibitors. For minimizing plasma sample instability and preanalytical variation, we suggest using an optimized blood collection device, minimizing the dwell time during blood collection and handling, controlling centrifugation and handling at room temperature, and saving plasma samples for use at most one freeze/thaw cycle. We have optimized our protocol to achieve reproducibility in peptidomic analyses of plasma samples using MALDI-TOF MS by minimizing preanalytical and analytical variability. © 2011 Springer Science+Business Media, LLC.